Huons Meditech said on Tuesday that it signed a memorandum of understanding with LVIS, a Silicon Valley-based digital brain disease diagnosis company, to commercialize its AI platform, NeuroMatch.

The software aims to innovate how neurological diseases are examined.

NeuroMatch, developed by LVIS, is a deep learning AI platform that analyzes neural circuits to diagnose diseases such as dementia and epilepsy. It also has the potential to suggest optimal neurological treatments, said a company official from Huons Meditech.

The two companies have agreed to jointly develop and produce medical devices for neuroanalysis which will complement the NeuroMatch software. 

Huons Meditech, which specializes in the production of medical and infection control devices, will be responsible for the commercialization of NeuroMatch.

LVIS was founded in 2013 by CEO Lee Jin-hyung, the first Korean woman appointed as a professor at Stanford University. With the creation of the software, the company has gained a competitive edge, backed by 20 patents and over 140,000 medical data sets collected over a span of 13 years.